View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Ph...

Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics Agreement Combines Tenaya’s Expertise in Identification and Validation ofGenetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to $10 Million in Upfront Payments in Addition to Research Funding and Milestone Payments of Up to $1.13 Billion SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stag...

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

4Q25 Postmortem: Evaluating AI Risk in the Current Landscape

In this report, we establish an initial framework to assess exposure to AI-enabled risk across our coverage group. Specifically, we evaluate the risk of replacement, disintermediation, or both. Our framework measures structural defensibility and business model differentiation against the difficulty

VRS RESEARCH TEAM
  • VRS RESEARCH TEAM

PALANTIR TECHNOLOGIES INC. [Bloomberg ticker: PLTR:US] Equity Research...

Palantir is transitioning into a scaled, commercially relevant AI platform provider. Historically defined by its government contracts, the company has reoriented its strategy around productized, enterprise-grade AI, most notably through the rapid expansion of its AIP. This shift has accelerated U.S. commercial growth, expanded margins, and established a pathway to durable profitability. Palantir Technologies Inc. is engaged in building software to assist in counterterrorism investigatio...

 PRESS RELEASE

Tenaya Therapeutics to Participate in the Leerink Partners Global Heal...

Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026 SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will be participating in the upcoming Leerink Partners Global Healthcare Conference taking place from March 9-11, 2026 in Miami, Florida. Faraz Ali, Tenaya’s Chief Executive Officer, wi...

 PRESS RELEASE

OPKO Health to Participate in the Jefferies Biotech on the Beach Summi...

OPKO Health to Participate in the Jefferies Biotech on the Beach Summit MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th. Investors interested in scheduling a meeting with OPKO management should contact their Jefferies representative. About OPKO Health OPKO is a multinational biopharmaceutic...

 PRESS RELEASE

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financ...

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This n...

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

600K Unit Margin Tune-Up; Outperform, $425 PT

Carvana reported strong revenue and unit growth, while GPU and adj. EBITDA were below expectations for 4Q. The company reported 4Q revenue of $5.6B (+58.0% Y/Y), ~7% ahead of St. expectations. While adj. EBITDA in the quarter was the highest quarterly amount the company has reported to date, totali

 PRESS RELEASE

OPKO Health to Report Fourth Quarter 2025 Financial Results on Februar...

OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-r...

Carvana Co: 1 director

A director at Carvana Co sold 1,047 shares at 398.540USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Alicia Reese ... (+11)
  • Alicia Reese
  • Anish Jog
  • Chase Tohanczyn
  • Daniel Ives
  • Kade Barr
  • Matthew McCartney
  • Matthew Weiss
  • Michael Piccolo
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
Alicia Reese ... (+11)
  • Alicia Reese
  • Anish Jog
  • Chase Tohanczyn
  • Daniel Ives
  • Kade Barr
  • Matthew McCartney
  • Matthew Weiss
  • Michael Piccolo
  • Sam Brandeis
  • Scott Devitt
  • Steven Wahrhaftig
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch